VXRT Live signals | Maximize Profits with Getagraph.com

SELL 115458 min ago

@ $1.235

Issued: 12 Feb 2024 @ 15:35

Return: -39.35%

Previous signal: Feb 12 - 14:01

Previous signal: Buy

Return: 2.06 %

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 16:00):

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform...

Stats
Today's Volume	1.23M
Average Volume	1.69M
Market Cap	132.45M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.140 ) 2024-06-11
Last Dividend	$12.19 ( 2012-11-09 )
Next Dividend	$0 ( N/A )
P/E	-1.310
ATR14	$0.00500 (0.68%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-28	Tucker Sean	Buy	0
2024-03-28	Tucker Sean	Sell	3 902	Common Stock
2024-03-28	Cummings James F.	Sell	3 292	Common Stock
2024-03-18	Tucker Sean	Buy	90 000	Common Stock
2024-03-18	Tucker Sean	Buy	410 000	Stock Option (right to buy)

INSIDER POWER
94.60
Last 95 transactions
Buy: 10 890 181 \| Sell: 279 805

Volume Correlation

Long: 0.38 (neutral)

Short: 0.10 (neutral)

Signal:(52.087) Neutral

Vaxart Inc Correlation

10 Most Positive Correlations
LYEL	0.934
LYRA	0.93
TCRT	0.92
FATE	0.92
WISA	0.915
GROM	0.914
AFMD	0.914
ARQQ	0.914
GRNA	0.913
AVO	0.912

10 Most Negative Correlations
LRFC	-0.93
STAY	-0.928
GLLI	-0.907
IBEX	-0.905
XOMAO	-0.899
XOMAP	-0.898
CHPM	-0.898
BCOR	-0.895
MNKD	-0.893
CIIG	-0.891

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vaxart Inc Correlation - Currency/Commodity

-0.52
( weak negative )

-0.50
( neutral )

0.00
( neutral )

0.49
( neutral )

Vaxart Inc Financials

Annual	2023
Revenue:	$7.38M
Gross Profit:	$2.88M (39.02 %)
EPS:	$-0.570

FY	2023
Revenue:	$7.38M
Gross Profit:	$2.88M (39.02 %)
EPS:	$-0.570

FY	2022
Revenue:	$107 000
Gross Profit:	$-3.16M (-2 953.27 %)
EPS:	$-0.840

FY	2021
Revenue:	$892 000
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.580

Financial Reports:

No articles found.

Vaxart Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Vaxart Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$12.19	2012-11-09
Last Dividend	$12.19	2012-11-09
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$12.19	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-03)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2012	$12.19	9.77%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-14.41	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.898	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-1.085	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.32	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.11	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.53	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0994	-1.500	8.34	-10.00	[0 - 0.6]
interestCoverageTTM	-57.60	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.459	2.00	-0.153	-0.306	[0 - 30]
freeCashFlowPerShareTTM	-0.471	2.00	-0.236	-0.471	[0 - 20]
debtEquityRatioTTM	0.158	-1.500	9.37	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.196	1.000	-0.0722	-0.0722	[0.2 - 0.8]
operatingProfitMarginTTM	-14.56	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-7.72	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0623	0.800	-2.92	-2.33	[0.5 - 2]
Total Score				-1.818

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.304	1.000	-0.233	0	[1 - 100]
returnOnEquityTTM	-1.085	2.50	-8.46	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.471	2.00	-0.157	-0.471	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.459	2.00	-0.153	-0.306	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00872	1.500	-3.28	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-12.31	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.58

Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.